Patents by Inventor Frank N. Chang
Frank N. Chang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200225235Abstract: A highly sensitive method of detecting GASP-1 or a fragment thereof in a sample is provided. The method comprises (a) exposing a surface to a sample comprising GASP-1 or a fragment thereof; (b) immobilizing an anti-GASP-1 detection antibody to the surface; (c) measuring the amount of the anti-GASP-1 detection antibody immobilized to the surface; and (d) determining the presence of the GASP-1 or a fragment thereof in the sample based on the amount of the anti-GASP-1 detection antibody immobilized to the surface. A coating agent may be immobilized to the surface in step (a), and the anti-GASP-1 detection antibody may be immobilized to the surface via the coating agent, directly or indirectly. The coating agent may be selected from the group consisting of a first GASP-1 fragment, a conjugate of a protein (e.g., bovine serum albumin (BSA)) and a GASP-1 peptide, a capture antibody against a microvesicle or exosomal surface biomarker, a capture antibody against a second GASP-1 fragment, and a combination thereof.Type: ApplicationFiled: March 23, 2020Publication date: July 16, 2020Applicant: Proplex Technologies, LLCInventors: Frank N. Chang, George P. Tuszynski, Solomon Luo, Jeff Yang
-
Publication number: 20190345256Abstract: A method for detecting cells having granules expressing G protein coupled receptor-associated sorting protein 1 (GASP-1) or a fragment thereof is provided. The detection method may comprise: (a) contacting the cells with an effective amount of a binding protein, wherein the binding protein comprises an antigen binding fragment that specifically binds GASP-1; and (b) identifying cells having granules bound to the binding protein. The GASP-1 granules may be in the cytosol or on the surface of the cells. Also provided are methods for producing T-cells comprising a chimeric antigen receptor, anti-GASP-1 antibody or a bi-specific binding protein. Further provided are methods for treating GASP-1-mediated to disease or inactivating exosomes, microvesicles or oncosomes.Type: ApplicationFiled: May 10, 2019Publication date: November 14, 2019Applicant: Proplex Technologies, LLCInventors: Frank N. Chang, George P. Tuszynski, Solomon Luo, Jeff Yang
-
Publication number: 20190269801Abstract: This application relates to dye-therapeutic moiety conjugates for imaging, targeting, and treating cancerous cells and/or tumors.Type: ApplicationFiled: October 21, 2017Publication date: September 5, 2019Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Leland W. K. Chung, Stefan Mrdenovic, Yi Zhang, Gina Chi-Yi Chu, Ruoxiang Wang, Frank N. Chang, George Paul Tuszynski
-
Publication number: 20190195881Abstract: A highly sensitive method of detecting GASP-1 or a fragment thereof in a sample is provided. The method comprises (a) exposing a surface to a sample comprising GASP-1 or a fragment thereof; (b) immobilizing an anti-GASP-1 antibody to the surface in the presence of the GASP-1 or a fragment thereof; (c) measuring the amount of the anti-GASP-1 antibody immobilized to the surface; and (d) determining the presence of the GASP-1 or a fragment thereof in the sample based on the amount of the anti-GASP-1 antibody immobilized to the surface. A coating agent may be immobilized to the surface in step (a), and the anti-GASP-1 antibody may be immobilized to the surface via the coating agent. The coating agent may be selected from the group consisting of a conjugate of bovine serum albumin (BSA) and a GASP-1 peptide (BSA-GASP-1 conjugate) a capture antibody against a microvesicle or exosomal surface biomarker, and a combination thereof. Also provided are kits for detecting GASP-1 or its fragment.Type: ApplicationFiled: December 20, 2018Publication date: June 27, 2019Applicant: Proplex Technologies, LLCInventors: Frank N. Chang, George P. Tuszynski, Solomon Luo, Jeff Yang
-
Publication number: 20190016821Abstract: An embodiment of the invention relates to the use of stabilized cancer peptide fragments derived from Protocadherin FAT1 for the diagnosis of cancers, particularly pancreatic cancer. A method for the detection of cancer, severity of cancer, and/or effectiveness of a therapeutic regimen includes detecting and/or measuring the amount of Protocadherin FAT1 peptide fragments present in the biological sample of a subject.Type: ApplicationFiled: January 5, 2017Publication date: January 17, 2019Applicant: Temple University of the Commonwealth System of Higher EducationInventor: Frank N. CHANG
-
Patent number: 9903871Abstract: An embodiment of the invention relates to the use of stabilized cancer peptide fragments derived from “redoxin proteins” selected from the group consisting of thioredoxin; peroxiredoxin-1, 2 and 3; glutaredoxin-3; glutathione peroxidase-4; and nucleoredoxins for the diagnosis of cancers, particularly pancreatic cancer. A method for the detection of cancer, severity of cancer, and/or effectiveness of a therapeutic regimen comprises detecting and/or measuring the amount of redoxin peptide fragments present in the biological sample of a subject.Type: GrantFiled: July 15, 2015Date of Patent: February 27, 2018Assignee: Temple University of the Commonwealth System of Higher EducationInventors: Frank N. Chang, George P. Tuszynski
-
Publication number: 20160018403Abstract: An embodiment of the invention relates to the use of stabilized cancer peptide fragments derived from “redoxin proteins” selected from the group consisting of thioredoxin; peroxiredoxin-1, 2 and 3; glutaredoxin-3; glutathione peroxidase-4; and nucleoredoxins for the diagnosis of cancers, particularly pancreatic cancer. A method for the detection of cancer, severity of cancer, and/or effectiveness of a therapeutic regimen comprises detecting and/or measuring the amount of redoxin peptide fragments present in the biological sample of a subject.Type: ApplicationFiled: July 15, 2015Publication date: January 21, 2016Applicant: Temple University of the Commonwealth System of Higher EducationInventors: Frank N. CHANG, George P. Tuszynski
-
Patent number: 9140704Abstract: Methods for identifying disease-specific markers, in particular breast cancer markers, by electrophoretically separating serum albumin complexes in a biological sample on a membrane are provided. Electrophoretic separation profiles representing different diseases or different cancer stages can be produced, and used in the diagnosis, prognosis and treatment of these diseases. Methods for identification of a cancer peptide fragment comprising a cancer peptide motif are provided. Also provided are breast cancer and other cancer markers and antibodies that specifically recognize these markers.Type: GrantFiled: July 13, 2010Date of Patent: September 22, 2015Assignee: Temple University of The Commonwealth System of Higher EducationInventors: Frank N. Chang, Phu T. Duong, George P. Tuszynski
-
Patent number: 8980269Abstract: A method for determining whether early stage cancer is present in a subject comprises detecting the expression level of GASP-1 in the subject by detecting the amount of GASP-1 peptide fragments present in a biological sample of the subject. Because cancer can be detected at an early stage, therapeutic targeting may be initiated before cancer reaches late stage (e.g., before the development of overt symptoms). A method for treating early stage cancer in a subject comprises administering to the subject an effective amount of a GASP-1 inhibitor to inhibit the progression of early stage cancer to late stage cancer. A Competitive ELISA capable of detecting GASP-1 peptide fragments at a concentration of less than 1 ng/ml was developed.Type: GrantFiled: March 13, 2013Date of Patent: March 17, 2015Assignee: Temple University of the Commonwealth System of Higher EducationInventors: Frank N. Chang, George P. Tuszynski
-
Patent number: 8420333Abstract: A method for determining whether early stage cancer is present in a subject comprises detecting the expression level of GASP-1 in the subject by detecting the amount of GASP-1 peptide fragments present in a biological sample of the subject. Because cancer can be detected at an early stage, therapeutic targeting may be initiated before cancer reaches late stage (e.g., before the development of overt symptoms). A method for treating early stage cancer in a subject comprises administering to the subject an effective amount of a GASP-1 inhibitor to inhibit the progression of early stage cancer to late stage cancer. A Competitive ELISA capable of detecting GASP-1 peptide fragments at a concentration of less than 1 ng/ml was developed.Type: GrantFiled: May 4, 2012Date of Patent: April 16, 2013Assignee: Temple University of the Commonwealth System of Higher EducationInventors: Frank N. Chang, George P. Tuszynski
-
Patent number: 8333880Abstract: Disease specific markers, in particular cancer markers, can be detected by electrophoretically separating proteins and protein complexes from a biological sample on a protein binding polymeric membrane in a low conductivity, water-miscible organic solvent buffer. Electrophoretic separation profiles representing different diseases can be produced, and used in the diagnosis or prognosis of these diseases.Type: GrantFiled: January 15, 2008Date of Patent: December 18, 2012Assignee: Temple University—Of The Commonwealth System of Higher EducationInventors: Frank N. Chang, Phu T. Duong, George P. Tuszynski
-
Publication number: 20120219570Abstract: A method for determining whether early stage cancer is present in a subject comprises detecting the expression level of GASP-1 in the subject by detecting the amount of GASP-1 peptide fragments present in a biological sample of the subject. Because cancer can be detected at an early stage, therapeutic targeting may be initiated before cancer reaches late stage (e.g., before the development of overt symptoms). A method for treating early stage cancer in a subject comprises administering to the subject an effective amount of a GASP-1 inhibitor to inhibit the progression of early stage cancer to late stage cancer. A Competitive ELISA capable of detecting GASP-1 peptide fragments at a concentration of less than 1 ng/ml was developed.Type: ApplicationFiled: May 4, 2012Publication date: August 30, 2012Applicant: Temple University of the Commonwealth System of Higher EducationInventors: Frank N. Chang, George P. Tuszynski
-
Publication number: 20120183555Abstract: Methods for identifying disease-specific markers, in particular breast cancer markers, by electrophoretically separating serum albumin complexes in a biological sample on a membrane are provided. Electrophoretic separation profiles representing different diseases or different cancer stages can be produced, and used in the diagnosis, prognosis and treatment of these diseases. Methods for identification of a cancer peptide fragment comprising a cancer peptide motif are provided. Also provided are breast cancer and other cancer markers and antibodies that specifically recognize these markers.Type: ApplicationFiled: July 13, 2010Publication date: July 19, 2012Applicant: Temple University of the Commonwealth System of Higher EducationInventors: Frank N. Chang, Phu T. Duong, George P. Tuszynski
-
Publication number: 20110031122Abstract: Disease specific markers, in particular cancer markers, can be detected by electrophoretically separating proteins and protein complexes from a biological sample on a protein binding polymeric membrane in a low conductivity, water-miscible organic solvent buffer. Electrophoretic separation profiles representing different diseases can be produced, and used in the diagnosis or prognosis of these diseases.Type: ApplicationFiled: January 15, 2008Publication date: February 10, 2011Applicant: Temple University of the Comonwealth System of Higher EducationInventors: Frank N. Chang, Phu T. Duong, George P. Tuszynski
-
Patent number: 7575858Abstract: A method of visualizing proteins bound to a protein-binding membrane is provided herein, comprising reacting proteins bound to protein-binding membranes with a compound of formula (I) wherein Ra, R1, R2, R3, R4, M, n, and m are as defined herein.Type: GrantFiled: September 9, 2003Date of Patent: August 18, 2009Assignee: Temple University—Of The Commonwealth System of Higher EducationInventors: Christopher R. Yonan, Frank N. Chang
-
Patent number: 7326326Abstract: Proteins can be rapidly separated to a high degree of resolution by electrophoresis on polymeric membranes that have high protein binding capacity. The electrophoretic separation is carried out in a low conductivity, water-miscible organic solvent buffer. The low conductivity of the organic solvent buffer minimizes heat generation, and the water-miscible nature of the organic solvent buffer permits the analysis of hydrophobic and low molecular weight proteins as well as hydrophilic proteins. When electrophoresis is conducted under non-denaturing conditions, it allows the detection of enzymatic activities, protein-protein interactions and protein-ligand interactions.Type: GrantFiled: September 9, 2003Date of Patent: February 5, 2008Assignee: Temple University-Of The Commonwealth System of Higher EducationInventors: Frank N. Chang, Christopher R. Yonan
-
Patent number: 7033777Abstract: The present invention is directed to a method and a test kit for detecting cockroach allergens and/or determining the total allergen level. A sample from an environment in which cockroaches are present or are suspected to be present is provided. The sample and a substrate composition comprising a chitinase substrate are then contacted. The presence of cockroach allergens can be determined by observing or detecting the magnitude of a measurable change of a property of the substrate composition following the contact between the sample and the substrate composition wherein the magnitude of the measurable change of a property of the substrate composition is proportional to the total allergen level. The total allergen level can be determined by measuring the magnitude of the measurable change of a property of the substrate composition, or by comparing the magnitude with a reference standard.Type: GrantFiled: March 19, 2003Date of Patent: April 25, 2006Assignee: Temple University of the Commonwealth System of Higher EducationInventors: Frank N. Chang, Phu T. Duong
-
Publication number: 20040121488Abstract: Proteins can be rapidly separated to a high degree of resolution by electrophoresis on polymeric membranes that have high protein binding capacity. The electrophoretic separation is carried out in a low conductivity, water-miscible organic solvent buffer. The low conductivity of the organic solvent buffer minimizes heat generation, and the water-miscible nature of the organic solvent buffer permits the analysis of hydrophobic and low molecular weight proteins as well as hydrophilic proteins. When electrophoresis is conducted under non-denaturing conditions, it allows the detection of enzymatic activities, protein-protein interactions and protein-ligand interactions.Type: ApplicationFiled: September 9, 2003Publication date: June 24, 2004Inventors: Frank N. Chang, Christopher R. Yonan
-
Publication number: 20030180826Abstract: The present invention is directed to a method and a test kit for detecting cockroach allergens and/or determining the total allergen level. A sample from an environment in which cockroaches are present or are suspected to be present is provided. The sample and a substrate composition comprising a chitinase substrate are then contacted. The presence of cockroach allergens can be determined by observing or detecting the magnitude of a measurable change of a property of the substrate composition following the contact between the sample and the substrate composition wherein the magnitude of the measurable change of a property of the substrate composition is proportional to the total allergen level. The total allergen level can be determined by measuring the magnitude of the measurable change of a property of the substrate composition, or by comparing the magnitude with a reference standard.Type: ApplicationFiled: March 19, 2003Publication date: September 25, 2003Inventors: Frank N. Chang, Phu T. Duong
-
Patent number: 5665370Abstract: An insecticidal product comprises a solid substrate impregnated with sterile cockroach aggregation pheromones, a sterile insecticidal composition comprises a solvent extract of the product, which may be in solution, and an insect attractant product comprises a solid substrate having the composition partially or fully coated thereon. The product and composition of the invention may be utilized in the manufacture of insect traps provided with a hollow receptacle and an opening, and optionally, a cover. An insect trap may comprise a hollow receptacle with a slippery internal surface to prevent the exit of the insects, and an opening, and optionally a cover. The present products are particularly suitable for trapping insects, such as cockroaches.Type: GrantFiled: February 22, 1995Date of Patent: September 9, 1997Assignee: Temple University Of The Commonwealth System Of Higher EducationInventors: Michael J. Gehret, Frank N. Chang